As a marker of minimal residual disease in B-cell acute lymphoblastic leukemia (B-ALL), CD58 has been reported in B-ALL at diagnosis and short-term follow-ups after standard chemotherapies. However, ...

The work is published in the journal Biomarker Research. B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common ...

B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases ...

SAN DIEGO -- Children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) lived significantly longer without disease recurrence when they received the bispecific T-cell engager ...

BREVARD COUNTY, FLORIDA – Sunday, April 27, 2025, at 1 p.m., the American Legion Post 200, 105 Ocean Blvd., Satellite Beach, Florida, will get behind and support 21-month-old cancer patient, Blakely ...

After 3.5 years of follow-up, there was a 98% rate of minimal residual disease, and 9 patients were still in complete remission.

2024 — Scientists have identified novel genetic variations that influence relapse risk in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood ...

Treatment consisted of 4-6 cycles of dose-dense intensive chemotherapy incorporating hyperfractionated ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...